Tag: stocks
TransDigm Group Stock Analysis: Buy or Sell? Leverage, Margins & Cash Flow
TransDigm Group (TDG) is a HOLD, with strong installed-base cash generation offset by a heavy balance sheet. Its 50.9% EBITDA margin supports the thesis, but 6.0x net debt/EBITDA limits upside and keeps refinancing risk in focus.
Kraft Heinz Stock Analysis: Buy or Sell? Valuation, FCF & Debt
Kraft Heinz (KHC) is rated Hold as strong cash generation offsets weak growth and negative net margin. Valuation looks fair, but revenue remains soft and debt is still the main risk to the thesis.
Constellium Stock Analysis: Buy or Sell? Valuation, FCF & Growth
Constellium SE (CSTM) is rated Hold as growth remains solid, but cash conversion is still too thin to justify a stronger call. The stock looks fairly valued on EV/EBITDA, yet weak free cash flow and customer concentration keep the risk profile elevated.
1-800-FLOWERS.COM Short Squeeze Analysis (FLWS): 79% of the Float Is Short
We are looking at a stock that checks the first box for a squeeze setup: a very large short position relative to the float. The latest short interest report shows 7.82M shares sold short, which is 79.0% of the 9.91M-share float and 21.1% of shares outstanding.
USA Rare Earth Stock Analysis: Buy or Sell? Valuation, Cash Burn & Growth
USA Rare Earth (USAR) earns a STRONG SELL rating as valuation races far ahead of operating reality. Revenue remains minimal while cash burn and massive capital needs keep the turnaround story dependent on execution.
Marathon Petroleum Stock Analysis: Buy or Sell? Valuation, Leverage & FCF
Marathon Petroleum (MPC) is rated Hold as strong cash generation and 13.6% operating margin are already reflected in the share price. The case hinges on whether EBITDA and free cash flow stay elevated while 1.7x net debt to EBITDA limits upside.
Boston Scientific Stock Analysis: Buy or Sell? Valuation & Growth Outlook
Boston Scientific (BSX) is rated Hold as strong organic growth and clinical momentum are offset by a valuation that already reflects much of the upside. The key question is whether BSX can keep growing fast enough to justify 13.4x EV/EBITDA while managing a $12.6B debt load.
Unusual Machines Stock Analysis: Buy or Sell? Valuation, Cash Burn & Growth
Unusual Machines (UMAC) earns a STRONG SELL rating because the valuation already prices in a clean operating turn that cash flow has not confirmed. Revenue is growing, but heavy cash burn, inventory risk, and a rich sales multiple leave little margin for execution errors.
Stryker Stock Analysis: Buy or Sell? Valuation, Margins & Risk
Stryker (SYK) is a HOLD as strong margins and free cash flow support the business, but the valuation already discounts much of that quality. Execution risk, including insider selling and a cyber incident, keeps the setup from looking cheap.
Semtech Stock Analysis: Buy or Sell? Valuation, FCF & China Risk
Semtech (SMTC) is rated STRONG SELL as its valuation already prices in a durable recovery that has yet to prove itself in cash. Strong free cash flow helps, but 111.4x trailing P/E, 70.1% debt/equity, and heavy China exposure leave too little margin of safety.